HIFU for Prostate Cancer: Procedure, Benefits, Risks and Who May Be Eligible

Quick Answer

HIFU stands for high-intensity focused ultrasound. It uses concentrated ultrasound energy to heat and destroy selected prostate tissue without making a surgical incision through the abdomen.

For prostate cancer, HIFU may be used as focal therapy to treat a selected cancer-containing area while trying to preserve surrounding prostate tissue. It may also be considered in carefully selected men whose cancer has returned locally after radiotherapy.

HIFU can offer advantages such as a shorter recovery and potentially lower rates of urinary incontinence or sexual dysfunction than whole-gland radical treatment in selected patients. However, it is important not to describe HIFU as proven superior to surgery or radiotherapy.

Current European guidance considers focal HIFU promising but emphasizes that long-term comparative cancer-control evidence remains limited. Salvage HIFU after radiotherapy has even less certain evidence and can cause substantial urinary and sexual complications.

HIFU is therefore not suitable for every man with prostate cancer. Eligibility depends on the cancer’s location, grade, stage, MRI and biopsy findings, prostate anatomy, previous treatment and the experience of the treating center.

What Is HIFU for Prostate Cancer?

HIFU is short for high-intensity focused ultrasound.

The technology concentrates multiple ultrasound waves on a small target inside the prostate.

Where those waves meet, tissue temperature rises rapidly enough to produce thermal destruction, also called ablation.

The idea is similar to using a magnifying lens to concentrate energy at one specific point: tissue along the pathway is exposed to much less energy than the focal treatment zone.

Is HIFU the Same as an Ultrasound Scan?

No.

Diagnostic ultrasound uses relatively low-energy sound waves to create images. HIFU uses much higher energy focused on a precise target so that the tissue is heated and destroyed.

The same treatment system may use ultrasound imaging to help the clinician see and target the prostate, but the therapeutic energy is much more intense than that used during routine imaging.

What Is Focal HIFU?

Focal HIFU means that only the cancer-containing region and an appropriate surrounding margin are intentionally treated, rather than destroying the entire prostate gland.

This is part of a broader approach called focal therapy.

The objective is to balance two competing goals:

• control clinically significant prostate cancer;
• while preserving as much normal prostate, urinary-sphincter and neurovascular tissue as reasonably possible.

Can the Entire Prostate Be Treated With HIFU?

Yes. HIFU can be used as whole-gland ablation in selected circumstances.

However, much of the modern interest in HIFU is focused on focal therapy because whole-gland treatment removes some of the tissue-sparing advantage.

The exact treatment field may be:

• a small focal area;
• one side or lobe of the prostate;
• a larger subtotal area;
• or the whole gland.

Which approach is used depends on where clinically significant cancer is located.

Who Might Be Considered for Focal HIFU?

There is no single simple rule such as “all low-grade prostate cancers can have HIFU.”

In fact, many men with genuinely low-risk prostate cancer may be better served by active surveillance rather than immediate ablation.

HIFU is generally discussed in selected men with localized, MRI-visible and biopsy-confirmed clinically significant disease where the cancer distribution appears suitable for focal treatment.

Before considering HIFU, clinicians generally need to understand:

• PSA;
• Grade Group/Gleason score;
• clinical stage;
• multiparametric MRI findings;
• targeted and systematic biopsy results;
• number and location of cancer foci;
• prostate size and anatomy;
• baseline urinary function;
• erectile function;
• and the patient’s priorities regarding cancer control and quality of life.

Is HIFU Recommended for Low-Risk Prostate Cancer?

Not automatically.

This is an important correction to the old article.

A man with low-risk localized prostate cancer may not benefit from immediate treatment at all. Current prostate-cancer management increasingly favors active surveillance for appropriately selected low-risk disease.

Destroying a low-risk tumor with HIFU can expose a man to treatment risks without necessarily providing an advantage over careful monitoring.

The decision therefore depends on the complete cancer risk profile rather than the phrase “low-grade cancer.”

What Does the HIFU Procedure Involve?

The exact protocol varies between treatment systems and centers, but HIFU is generally performed under anesthesia or sedation.

A treatment probe is typically placed in the rectum next to the prostate. The system uses imaging to map the treatment area and then delivers focused ultrasound energy to successive small regions of prostate tissue.

The target tissue is heated sufficiently to cause coagulative necrosis—the treated cells lose viability and subsequently break down.

Because the energy is delivered internally through the rectum, no large abdominal incision is required.

Why Is the Probe Placed in the Rectum?

The prostate is located immediately in front of the rectum.

This provides a relatively short pathway for ultrasound energy to reach the gland and allows accurate imaging and targeting.

The goal is not to heat the rectum itself. Treatment planning and device controls are designed to focus the high-energy zone inside the prostate while limiting exposure to surrounding structures.

How Long Does HIFU Take?

Procedure time varies considerably according to:

• prostate size;
• tumor location;
• amount of tissue being treated;
• whether focal or whole-gland ablation is performed;
• and the treatment system used.

Patients should ask the treating center for the expected procedure time rather than assuming HIFU is always a short outpatient procedure.

Will I Need a Urinary Catheter?

Often, yes.

HIFU produces inflammation and swelling in the treated prostate tissue. This can temporarily obstruct urinary flow.

A urethral or suprapubic catheter may therefore be required after treatment. The duration varies according to the procedure and postoperative urinary function.

Do You Stay in Hospital After HIFU?

Many patients can leave the hospital the same day or after a short stay, depending on local practice, anesthesia, catheter management and recovery.

I would not promise every patient discharge within 24 hours because clinical circumstances vary.

What Are the Potential Benefits of HIFU?

The most attractive feature of focal HIFU is the possibility of treating the known clinically important tumor while preserving more surrounding tissue than radical whole-gland treatment.

Potential advantages include:

• no abdominal surgical incision;
• relatively short hospitalization in many cases;
• faster initial recovery than major prostate surgery for many patients;
• lower risk of severe urinary incontinence in many focal-treatment series;
• greater potential to preserve erectile function compared with whole-gland therapy in appropriately selected patients;
• and the possibility of additional local treatment if cancer remains or returns in selected cases.

Does HIFU Have Fewer Side Effects Than Surgery?

Potentially, particularly when a limited focal area is treated—but the answer needs qualification.

The EAU’s current evidence review of focal therapies reports encouraging functional outcomes, including very high rates of pad-free continence in short-term series. However, these studies are not equivalent to having decades of randomized comparative evidence against radical prostatectomy and modern radiotherapy.

Patient selection also matters greatly: men chosen for focal HIFU often have different disease characteristics from men undergoing radical treatment.

Therefore, it is more accurate to say:

Does HIFU Cure Prostate Cancer?

It can successfully ablate clinically significant cancer in selected patients, but I would not describe it as a guaranteed cure.

There are two important reasons.

First, prostate cancer can be multifocal, meaning more than one cancer focus can exist within the gland. Imaging and biopsy improve mapping but cannot provide perfect certainty that every significant focus has been found.

Second, some men have residual or recurrent cancer after focal treatment and may need:

• repeat HIFU;
• another focal therapy;
• radiotherapy;
• radical prostatectomy;
• or other treatment depending on the situation.

In EAU-reviewed focal-therapy cohorts, retreatment was required in a meaningful minority of patients. :contentReference[oaicite:2]{index=2}

How Strong Is the Evidence for HIFU?

Evidence has improved considerably, but uncertainty remains.

The current EAU prostate-cancer guideline reports medium-term observational outcomes for focal therapy extending to approximately eight years in some datasets. It also emphasizes important limitations, including patient-selection bias and the relative scarcity of robust randomized comparisons with radical treatment. :contentReference[oaicite:3]{index=3}

NICE similarly concludes that the available safety evidence for focal HIFU is adequate but that evidence of efficacy remains limited. It therefore recommends special arrangements for governance, consent, audit or research. :contentReference[oaicite:4]{index=4}

What Are the Side Effects of HIFU?

The frequency depends strongly on whether treatment is focal or whole-gland, whether the patient previously received radiotherapy and how much prostate tissue is treated.

Can HIFU Cause Erectile Dysfunction?

Yes.

Preserving erectile function is one of the main goals of focal HIFU, but preservation is not guaranteed.

Risk depends partly on:

• erectile function before treatment;
• age and vascular health;
• tumor location;
• distance from the neurovascular bundles;
• and the amount of tissue treated.

A tumor very close to the nerves responsible for erections may require a wider treatment margin and therefore increase sexual risk.

Can HIFU Cause Urinary Incontinence?

Yes, although persistent significant incontinence appears relatively uncommon after appropriately selected focal HIFU in modern series.

That should not be translated into “HIFU does not cause incontinence.”

Whole-gland treatment and salvage treatment after previous radiotherapy can have substantially higher complication rates than primary focal HIFU.

Can HIFU Cause a Rectourethral Fistula?

Rarely, yes.

A rectourethral fistula is an abnormal connection between the rectum and urinary tract.

It is uncommon in modern primary focal treatment but is a recognized serious complication, with higher risk in previously irradiated tissues.

What Is Salvage HIFU?

Salvage HIFU refers to HIFU used when prostate cancer has returned locally after previous radiotherapy.

This is very different from primary focal HIFU in an untreated prostate.

Radiation permanently changes tissue quality, blood supply and healing. Therefore, complication rates can be substantially higher when HIFU is used in an irradiated prostate.

How Effective Is Salvage HIFU After Radiation?

Current evidence is substantially less certain than for established primary treatments.

The EAU reviewed a meta-analysis involving 20 salvage-HIFU studies and 1,783 patients. Adjusted biochemical recurrence-free survival was approximately 54% at two years and 53% at five years, but the certainty of evidence was low. :contentReference[oaicite:5]{index=5}

The EAU also reports substantial variability in complications, including urinary incontinence, obstruction or retention, erectile dysfunction and rectourethral fistula. :contentReference[oaicite:6]{index=6}

Who Should Consider Salvage HIFU?

This is not a treatment for every man whose PSA rises after radiation.

A rising PSA does not by itself prove that recurrent cancer is confined to the prostate.

Before considering local salvage therapy, clinicians generally need to establish that:

• recurrence has genuinely occurred;
• clinically significant cancer is confirmed locally, usually by biopsy;
• there is no evidence that metastatic disease is driving the recurrence;
• life expectancy and general health justify additional local treatment;
• and the expected benefits outweigh the increased complication risk.

The EAU recommends salvage HIFU only for highly selected patients with biopsy-proven local recurrence in a clinical-trial setting or well-designed prospective cohort at an experienced center. :contentReference[oaicite:7]{index=7}

Is HIFU Appropriate for Locally Advanced Prostate Cancer?

Not as routine primary treatment.

The EAU states that HIFU and other focal therapies currently have no established role in management of locally advanced prostate cancer. :contentReference[oaicite:8]{index=8}

NICE similarly does not recommend HIFU for locally advanced disease outside controlled clinical trials. :contentReference[oaicite:9]{index=9}

Is HIFU Used for Metastatic Prostate Cancer?

HIFU is not a standard curative treatment for prostate cancer that has spread to distant organs or bones.

Metastatic disease requires systemic treatment because destroying one area inside the prostate cannot eliminate cancer cells elsewhere in the body.

Treatment may include androgen-deprivation therapy and other systemic therapies according to disease state and risk.

HIFU vs Active Surveillance

For men with low-risk prostate cancer, this may be one of the most important comparisons.

For appropriately selected low-risk disease, active surveillance may offer an important advantage: avoiding treatment entirely unless there is evidence that treatment becomes necessary.

HIFU vs Radical Prostatectomy

Radical prostatectomy removes the entire prostate and seminal vesicles and has long-established oncological outcome data.

Focal HIFU treats less tissue and generally offers a faster initial recovery, with potentially less urinary and sexual morbidity in selected men.

The trade-off is that focal HIFU leaves untreated prostate tissue in place and has less mature long-term comparative evidence.

Some men who develop recurrence after focal therapy can subsequently undergo radical prostatectomy, although salvage surgery may be technically more complex.

HIFU vs Radiotherapy

External-beam radiotherapy treats prostate cancer using ionizing radiation delivered from outside the body.

HIFU uses focused ultrasound energy and does not expose the prostate to ionizing radiation.

However, describing ultrasound as “harmless” would be incorrect. The entire purpose of therapeutic HIFU is to destroy tissue through intense heating.

Radiotherapy has much more mature long-term evidence for cancer control in appropriate localized and locally advanced disease.

Can HIFU Be Repeated?

Repeat focal HIFU may be possible in selected men when residual or recurrent disease remains suitable for another focal treatment.

But the old article’s suggestion that HIFU can simply be repeated without concern because ultrasound is harmless is too reassuring.

Every additional treatment can produce:

• more scar tissue;
• greater urinary obstruction;
• changes in sexual function;
• and increased complexity if later salvage surgery is required.

Retreatment should therefore be an oncological decision rather than an assumed benefit of the technology.

What Happens to PSA After HIFU?

PSA usually falls after HIFU because prostate tissue has been destroyed, but the interpretation differs from radical prostatectomy.

After radical prostatectomy, essentially all prostate tissue has been removed, so PSA is expected to become very low or undetectable.

After focal HIFU, healthy prostate tissue remains and continues to produce PSA. There is therefore no single PSA number that proves focal treatment succeeded or failed.

PSA trends must be interpreted together with imaging, examination and, when indicated, repeat biopsy.

Do I Still Need MRI or Biopsy After HIFU?

Yes, surveillance remains essential.

Because focal HIFU intentionally leaves prostate tissue untreated, follow-up usually involves more than PSA alone.

Depending on the treatment protocol, follow-up may include:

• serial PSA testing;
• multiparametric MRI;
• clinical review;
• targeted biopsy;
• and systematic biopsy at specified intervals.

EAU guidance emphasizes systematic biopsy in men being considered for focal therapy because clinically significant disease elsewhere in the prostate needs to be excluded as well as possible. :contentReference[oaicite:10]{index=10}

Is HIFU FDA Approved?

This point requires careful wording.

The FDA has cleared high-intensity ultrasound systems for prostate tissue ablation. For example, the FDA device database lists the Focal One system under the classification “High Intensity Ultrasound System for Prostate Tissue Ablation.” :contentReference[oaicite:11]{index=11}

FDA clearance of a device should not be interpreted as meaning that HIFU is the recommended treatment for every prostate-cancer risk group.

Clinical appropriateness still depends on cancer characteristics, guidelines, local expertise and shared decision-making.

Dr. Albana’s Perspective

I would describe HIFU as an important but selective prostate-cancer treatment, not as a simple replacement for surgery or radiotherapy.

The most attractive aspect of focal HIFU is that it may allow a urology team to treat the clinically significant cancer while preserving more normal prostate and surrounding tissue.

For the right patient, that can mean an appealing balance between cancer treatment and quality of life.

But the choice begins with one important question: Does this cancer need immediate treatment at all?

A man with genuinely low-risk disease may be better suited to active surveillance. A man with cancer that is too extensive, multifocal or advanced may need an established whole-gland or systemic treatment instead.

If HIFU is being considered after previous radiotherapy, I would be even more cautious. Salvage HIFU can be appropriate for selected biopsy-confirmed local recurrence, but complication rates can be substantially higher and current guidelines emphasize treatment in experienced centers and prospective study settings.

My role as a family physician is to help a patient understand these trade-offs. The final decision about whether HIFU is technically and oncologically suitable should be made with a urologist or prostate-cancer multidisciplinary team that can review the MRI, biopsy, PSA, stage, prostate anatomy and all alternative treatments.

— Dr. Albana Greca, MD, MMedSc
Family Physician / General Practitioner

Questions to Ask Before Choosing HIFU

• What is my exact Grade Group and Gleason score?
• Is my cancer truly confined to the prostate?
• How many cancer areas were found on MRI and biopsy?
• Is the cancer suitable for focal rather than whole-gland treatment?
• Would active surveillance be a reasonable option?
• Why is HIFU preferable to surgery or radiotherapy in my specific case?
• How many HIFU procedures has this center performed?
• What are this center’s rates of retreatment?
• What are its rates of urinary retention, incontinence and erectile dysfunction?
• Will I need a catheter afterward?
• How will my PSA be monitored?
• When will I have another MRI?
• Will I need a repeat biopsy?
• What happens if HIFU does not eliminate all clinically significant cancer?
• Can I still have surgery or radiotherapy afterward?

When to Seek Prompt Medical Care After HIFU

After treatment, contact the treating team promptly for:

• inability to urinate or a catheter that stops draining;
• fever or chills;
• severe or worsening pelvic pain;
• heavy or persistent urinary bleeding;
• severe rectal pain or bleeding;
• urine passing through the rectum;
• or significant deterioration in general health.

Some urinary discomfort can occur during recovery, but severe symptoms should not simply be assumed to be normal after ablation.

Frequently Asked Questions

What does HIFU stand for?

HIFU means high-intensity focused ultrasound. It concentrates ultrasound energy inside selected prostate tissue to generate enough heat to destroy that tissue.

Is HIFU surgery?

It is a procedural treatment rather than conventional open surgery. It usually does not require an abdominal incision, but it still intentionally destroys prostate tissue and generally requires anesthesia and postoperative monitoring.

Is HIFU suitable for all localized prostate cancers?

No. Suitability depends on cancer grade, stage, MRI and biopsy findings, tumor location, prostate anatomy and patient priorities. Some low-risk cancers may be better monitored with active surveillance, while more extensive disease may require established radical treatment.

Is HIFU better than prostate surgery?

Not universally. Focal HIFU may offer lower functional toxicity in selected patients, while radical prostatectomy has much more mature long-term cancer control data. The appropriate option depends on the individual cancer.

Can HIFU cause erectile dysfunction?

Yes. The risk may be lower with carefully planned focal treatment than with whole-gland treatment, but erectile function can still deteriorate.

Can HIFU cause urinary incontinence?

Yes, although persistent significant incontinence appears relatively uncommon in many primary focal-HIFU series. Risks are higher in some whole-gland and salvage settings.

Can prostate cancer return after HIFU?

Yes. Cancer may remain in the treated zone, recur there later or be detected in an untreated part of the prostate. Long-term surveillance is therefore necessary.

Can HIFU be repeated?

Repeat focal treatment may be possible in selected patients, but it is not risk-free. Additional treatment can increase scarring and urinary or sexual complications.

Can HIFU be used after radiotherapy?

Yes, salvage HIFU is sometimes considered for highly selected men with biopsy-confirmed local recurrence after radiotherapy. Current evidence is limited and complication rates can be significant, so treatment should be performed in experienced specialist centers.

Does PSA become zero after focal HIFU?

Usually not. Untreated prostate tissue remains after focal therapy and continues to produce PSA. Follow-up therefore relies on PSA trends together with MRI, clinical assessment and often repeat biopsy.

Related Prostate Cancer Guides

Medical References

1. European Association of Urology. EAU Guidelines on Prostate Cancer — Treatment.
   EAU Prostate Cancer Treatment Guideline
2. National Institute for Health and Care Excellence. Focal Therapy Using High-Intensity Focused Ultrasound for Localised Prostate Cancer.
   NICE HIFU Guidance
3. National Institute for Health and Care Excellence. Prostate Cancer: Diagnosis and Management.
   NICE Prostate Cancer Guideline
4. U.S. Food and Drug Administration. High Intensity Ultrasound System for Prostate Tissue Ablation.
   FDA Device Database
5. National Cancer Institute. High-Intensity Focused Ultrasound for Radiorecurrent Localized Prostate Cancer — Clinical Trial.
   NCI HIFU Clinical Trial